source
- Braveheart Bio raises $382.5M in IPO to fund phase 3 trial of cardiac drugBraveheart Bio, a San Francisco biotech, completed an IPO that raised $382.5 million, exceeding its original target. The company increased the share count to 21.2 million and set the price at $18…
- BioVie shares plunge as Parkinson’s trial results lack primary motor dataBioVie reported results of its Phase 2 SUNRISE-PD study in early‑stage Parkinson’s disease. The double‑blind, placebo‑controlled trial enrolled 57 patients who had not yet received carbidopa/levodo…